Endocrinology Drugs Market by Therapy Area, Distribution channel, and Geography - Forecast and Analysis 2023-2027

Endocrinology Drugs Market Analysis Report 2023-2027: 

The endocrinology drugs market size is estimated to grow at a CAGR of 7.82% between 2022 and 2027. The endocrinology drugs market size is forecast to increase by USD 36,551.24 million. The growth of the market depends on several factors, including the increase in the incidence of endocrine disorders, the promising pipeline for endocrinology, and the research in novel dosage formulations and drug delivery systems.

This market report extensively covers market segmentation by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), therapy area (diabetes drugs, HGH, thyroid hormone, others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

 What will the size of the Endocrinology Drugs Market be During the Forecast Period?

To learn more about this report, View Report Sample

Endocrinology Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increase in the incidence of endocrine disorders is notably driving the endocrinology drugs market growth, although factors such as the patent expiry on major endocrinology drugs may impede the market growth. Our researchers studied the data for years, with 2022 as the base year and 2023 as the estimated year, and presented the market's key drivers, trends, and challenges. Although there has been a decrease in demand for the market during the COVID-19 pandemic, a holistic analysis of drivers will help companies refine marketing strategies to gain a competitive advantage.   

Key Endocrinology Drugs Market Driver

The increase in the incidence of endocrine disorders is notably driving the endocrinology drug market growth. The increase in the incidence of endocrine disorders may be attributed to the rising aging population globally. An aging population is a high-risk group for hormonal disorders that increase with age. With advances in technology, life expectancy is increasing worldwide. This increases the proportion of the aging and dependent population, which, in turn, poses a significant burden on public healthcare spending and the average spending per person on healthcare. A trend that is generally seen in endocrine disorders such as diabetes is that the incidence is generally higher in low- and middle-income countries. Diabetes is the most common endocrine disorder, and its prevalence is increasing globally, making it a major public health issue.

The risk factors are generally known to be genetic besides poor lifestyle and dietary habits. However, there is inadequate knowledge of factors such as the intra-uterine environment and epigenetics that could be controlled to reduce the incidence of the disease. If the epigenetic changes that increase the risk of diabetes are understood, the chances of disease incidence in adulthood may be reduced. The incidence of diabetes also has a high economic impact globally due to the associated costs. The direct costs associated with diabetes include hospital costs, those associated with purchasing drugs and biologics, primary care and visits, and specialized visits. Hence, the increasing incidence of endocrine disorders and the rising aging population that is at high risk for these diseases are major drivers for the market.

Key Endocrinology Drugs Market Trends

The association between obesity and endocrine disorders is the primary trend driving the endocrinology drug market growth. The increasing prevalence of obesity may be associated with the high incidence of endocrine disorders such as diabetes, hypothyroidism, and PCOS. Obesity may also be associated with rare endocrine disorders such as Cushing's Syndrome and hypothyroidism. These disorders may be the causative factors for the development of obesity in some cases or may be the secondary effects of obesity. Endocrine disorders that result from obesity can generally be controlled through weight loss. Obesity may also be a clinical manifestation of disorders such as Cushing's Syndrome, decreased growth hormone levels, testosterone deficiency, and PCOS. It may result in endogenous hormonal system alterations in some patients.

The strongest correlation is seen in the case of hypothyroidism and obesity, as the latter leads to reduced metabolic efficiency, increased water retention, and decreased lipolysis. Due to these reasons, obesity, type-2 diabetes mellitus, and thyroid diseases are the most common endocrine disorders and generally coexist in the same patient in most cases. Among these, diabetes is generally the secondary effect of obesity while hypothyroidism is the causative reason. The relative deficiency of growth hormones noticed in obese individuals is also seen as a maladaptive consequence. Sedentary lifestyles, smoking, and bad dietary choices are the most common reasons cited for both endocrine and obesity prevalence globally.

Key Endocrinology Drugs Market Challenge

Patent expiry on major endocrinology drugs is the major challenge impeding the endocrinology drugs market growth. Endocrinology drugs have been in the market since 1995 when the US FDA approved Wyeth's PREMPRO and PREMPHASE, conjugated estrogens/medroxyprogesterone acetate tablets for use as post-menopausal hormone replacement therapy in patients with post-menopausal osteoporosis. Many of the earlier approved drugs witnessed the expiry of their patents. For instance, Lantus, the world's most widely prescribed insulin, was a major revenue generator in the market before losing its patent in February 2015. Humalog's patent expired in 2013, and NovoLog/NovoRapid's patent expired in 2014. Humulin's and Novolin's patents expired in 2001 and 2002, respectively. Patents on many blockbuster anti-diabetes drugs have expired or will expire during the forecast period. They include BYETTA and Victoza in 2017, APIDRA in June 2018, and JANUVIA in 2022.

Patent expiry means the subsequent entry of generic drugs and the loss of market share by branded drugs along with downward pricing pressure. Strategies used by manufacturers to manage patent loss and erosion of their market share by generics include using clustered patents and filing patent litigations. These steps may delay the entry of generics and biosimilars for an extended period. The affordability and accessibility of treatment for many endocrine disorders have improved with the entry of biosimilars post-patent expiry on branded drugs. However, these drugs still face market access barriers in the form of payer resistance. 

Key Endocrinology Drugs Market Customer Landscape

Our analysis of the life cycle of the market indicates a movement from the innovator’s stage to the laggard’s stage. Technavio has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop growth strategies from 2022 to 2027.

Global Endocrinology Drugs Market Customer Landscape

Who are the Major Endocrinology Drugs Market Vendors?                                     

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market

Takeda Pharmaceutical  - The company offers endocrinology drugs such as Nesina and Kazano. Under this segment, the company generates revenue from a single operating segment that focuses on the research, development, manufacturing, and marketing of pharmaceutical products.

We  also have detailed analyses of the market’s competitive landscape and offer information on 15 market vendors, including :

• Abbott Laboratories
• Acerus Pharmaceuticals Corp.
• Ascendis Pharma AS
• Bayer AG
• Beta Cell NV
• Biocon Ltd.
• Eli Lilly and Co.
• Endo International Plc
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hanmi Pharm Co. Ltd.
• Ipsen Pharma
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk AS
• Oramed Pharmaceuticals Inc.
• Pfizer Inc.
• Sanofi SA
• VeroScience LLC

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Endocrinology Drugs Market?

The market share growth by the diabetes drugs segment will be significant during the forecast period. The diabetes drugs segment dominated the market in 2022. Diabetes is among the most common non-communicable diseases globally. Three major types of diabetes include type-1 diabetes, type-2 diabetes, and gestational diabetes. In type-1 diabetes, the pancreatic cells that make insulin are destroyed. Risk factors for type-2 diabetes may be either modifiable or non-modifiable factors. The modifiable risk factors include lifestyle factors such as obesity, physical inactivity, and bad dietary habits, whereas non-modifiable risk factors include family history and advancing age. Several comorbidities are associated with type-2 diabetes, including chronic kidney disease, cardiovascular disease, hypertension, and dyslipidemia. 

Get full insights on the market contribution of various segments Request a PDF Sample

The diabetes drugs segment showed a gradual increase in market share with USD 4,8743.16 million in 2017 and will continued to grow by 2021. The diabetes drugs segment is expected to witness accelerating growth, mainly due to the increased incidence of diabetes globally. This indication, which was typically considered a disease with the onset of aging and in obese individuals, is now showing incidence in young and middle-aged people as well as non-obese individuals. The increase in market size could also be attributed to the recent trend of using diabetes drugs as off-label medication for weight loss.  Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.

The growth of this segment is primarily attributed to the increasing adoption of endocrinology drugs, which is driven by an increase in the global demand for the endocrinology drugs industry.

Which are the Key Regions for the Endocrinology Drugs Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 45% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market in North America is expected to experience an accelerating growth momentum due to the growing aging population, which increases the risk of endocrine disorders. The increase in the cases of obesity in the US and Canada can be associated with the increase in the incidence of various endocrine disorders, such as diabetes, insulin resistance, and thyroid problems. The high incidence of diabetes, which is the most common endocrine disorder, is a key revenue contributor to the regional market. Patient education initiatives by organizations such as the American Diabetes Association and the American Association of Diabetes Educators also drive market growth in the region. Furthermore, the education programs conducted by the CDC and the National Institute of Diabetes and Digestive and Kidney Diseases for healthcare professionals are expected to drive market growth. 

In 2020, the outbreak of COVID-19 negatively affected all countries in North America, especially the US. It also had a slightly negative impact on the market in North America. Widespread measures, including temporary closures of non-essential businesses, event cancellations, travel restrictions, quarantines, and other disruptive actions, were deployed by several countries worldwide to prevent the disease from spreading. Thus, various non-urgent treatments and clinical visits were either limited or completely halted during the pandemic, resulting in declining demand for endocrinology drugs, which negatively impacted the growth of the regional market in 2020. However, in 2021, business and industrial activities resumed with the relaxation of stringent lockdown restrictions due to the availability of COVID-19 vaccines and the vaccination drives carried out by the governments of different countries, such as the US, Canada, and Mexico. The relaxation of such restrictions will encourage people to go for health checkups and treatments, which will drive the market growth in North America in 2022, which is expected to continue during the forecast period as well. 

Parent Market Analysis

Technavio categorizes the endocrinology drugs market as a part of the global pharmaceuticals market within the overall healthcare industry.  The parent, the global pharmaceuticals market, covers products and companies engaged in R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Segment Overview

Our endocrinology drugs market report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by therapy area, distribution channel, and region.

• Therapy Area Outlook (USD Million, 2017 - 2027)
  • Diabetes drugs
  • HGH
  • Thyroid hormone disorders
  • Others

• Distribution Channel Outlook (USD Million, 2017 - 2027)
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

• Region Outlook (USD Million, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Latin America
    • South Africa
    • Rest of the Middle East & Africa

Endocrinology Drugs Market Scope
Report Coverage	Details
Page number	172
Base year	2022
Historical year	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 7.82%
Market growth 2023-2027	USD 36,551.24 million
Market structure	Fragmented
YoY growth (%)	6.52
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 45%
Key consumer countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading companies, Competitive Strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck & Co. Inc., Novartis AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Get access to Report Sample PDF !

What are the Key Data Covered in this Endocrinology Drugs Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the endocrinology drugs market between 2023 and 2027
• Precise estimation of the endocrinology drugs market size and its contribution to the parent market.
• Accurate predictions about  upcoming trends and changes in consumer behavior
• Growth of the endocrinology drugs industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive details of factors that will challenge the growth of endocrinology drugs market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch